Among these Treg-eliminating chemotherapeutic agents, the effect of CY has been well-studied, providing compelling evidence that it eliminated tumor-associated TNFR2-expressing Tregs in both human patients and in mouse tumor models15. This evidence concerns the gene TNFRSF1B and neoplasm.